

Summary findings from:  
**“ATTCs, clinical infrastructure  
requirements and adoption of  
ATMPs” workshop**

19 September 2018

# Introduction

On 19 September 2018 members of the organisations listed here met to address in an open and unattributed way what needs to be done to facilitate the adoption of Advanced Therapy Medicinal Products (ATMPs) in the UK NHS system. This document summarises the outputs of both the morning and afternoon sessions.



## Organisations represented

ABPI  
Anthony Nolan  
Atelerix  
Bayer  
Bellicum  
Pharmaceuticals  
BIA  
BioMarin  
Pharmaceutical  
bluebird bio  
Celgene  
Cell Medica  
Covance  
Deltohn Ltd  
Dignio  
Exmoor Pharma  
Gilead Sciences  
Health Innovation  
Network

Horizon Discovery  
Health Research  
Authority  
iMATCH – Manchester  
Advanced Therapy  
Treatment Centre  
Innovate UK / UKRI  
Janssen-Cilag Ltd  
Knowledge Transfer  
Network  
London Advanced  
Therapy Network  
MHRA  
Midland & Wales  
Advanced Therapy  
Treatment Centre  
Muscular Dystrophy UK  
NHS England


NHS Scotland  
NHS Wales  
NICE  
Northern Alliance  
Advanced Therapies  
Treatment Centre  
Novartis  
Orchard  
Therapeutics  
Pfizer  
Sanofi  
Scottish Medicines  
Consortium  
TrakCel  
Valid Insight  
Videregen  
Welsh Health  
Specialised Services  
World Courier  
Services

Morning Session:

# Advanced Therapy Treatment Centres and NHS clinical infrastructure

---

# Advanced Therapy Treatment Centre network



**The network of Advanced Therapy Treatment Centres will develop and deliver systems for the delivery of cutting edge cell and gene therapies.**

- The network will increase the ability of the NHS to deliver disruptive medicines
- The centres will develop systems and processes within the trusts and hospitals capable of delivering advanced therapies at scale to patients across the NHS
- The learnings and systems from the initial centres will be rolled out to other centres in the UK

# ATTC and ATN areas of focus

## Northern Alliance Advanced Therapies Treatment Centre



- Supply chain, starting material procurement, secondary manufacturing, handling by clinicians and long term follow up, informatics infrastructure
- Stress test the system using four exemplars with different challenges particularly on the supply chain
- Evaluate the modality of distributed manufacturing

## iMATCH – Manchester Advanced Therapy Centre Hub



- Developing a coordinated strategy to scale up advanced therapies for patients
- Maximising access to patients
- Delivering electronic sample traceability and tracking systems
- Maximising efficiency, data capture
- Clinical scaling-up activity
- Safe delivery of ATMPs with end to end training and education

## MW-ATTC - Midlands & Wales Advanced Therapy Treatment Centre




- Developing a patient and public engagement strategy
- Electronic capture of patient recorded reported outcome data such as quality of life, adverse events, feedback to the clinical team
- Development of a trial acceleration programme for cellular therapies (TAP-CT)
- Focus on health economics and clinical pathway mapping

## London Advanced Therapies Network (ATN)

- Connecting capabilities in advanced therapies in London – Knowledge exchange
- Rapid resolution of IP problems within London – uniform protocols to allow third parties to interact with London in a single transaction in 14 days max
- Training: development of short courses that can meet these skills gaps

Cell and Gene Therapy Catapult coordination

# What is required to accelerate adoption



The ATTC network will work together with its partners to address the identified priorities to ensure they provide easily-run and ready to use systems and solutions that can then be rolled out to other NHS centres, leading to enhanced patient access to ATMPs.

---

Afternoon session:

# Affordability, payment and reimbursement of cell and gene therapies

---



# Recurrent themes

---

There were many points raised, but a group of issues which came up repeatedly:

---




The high degree of novelty and the early stage creates an even greater need and opportunity for **patient involvement**.



There are many areas where there is a need to invest in new ways of **gathering, handling, and interpreting data**.




There is an opportunity to adopt new ways of following **patient progress**, including taking advantage of new technology.



There is an increased need to plan ahead for the investment in the **infrastructure** to accommodate novel ways of operating.



The scale of expected growth and change is not well understood; there is a need for information and forecasts for **planning** purposes.




There is a need for development of novel, workable and mutually beneficial payment process, such as **outcomes-based payments**.




There is need to ensure **political support** through understanding of the potential of ATMPs to be transformative, at all levels.


# Where individual companies can lead:




# Where National Health Services (NHS) can lead:




# Where “Regulators and Market Access stakeholders” can lead:




# Where political decision makers can lead:



# Where “intermediary” organisations can lead:



# Where patients and patient organisations can lead:



# What next?

---

Individual organisations can and will create their own agendas going forward. Nonetheless, it is necessary for all the different stakeholders to come together to tackle these issues, as it is too big task for any one group to drive, and it is in everyone's interest to resolve.

Any organisation seeking help or input in coordinating a further action or collaboration in this area should feel free to contact the Cell and Gene Therapy Catapult.

The Cell and Gene Therapy Catapult, through its coordinating role in the ATTC network and its “Proof of Adoption” strategic priority, will monitor progress over the coming months.

Regular consultation is anticipated to measure progression and impact.

This is just a starting point for a series of actions. It is hoped that, through this workshop, its outputs and the subsequent discussions, no critical area will be neglected or forgotten in the complementary activities that follow.

For more information contact us at [comms@ct.catapult.org.uk](mailto:comms@ct.catapult.org.uk)



# CATAPULT

## Cell and Gene Therapy

12th Floor Tower Wing  
Guy's Hospital  
Great Maze Pond  
London SE1 9RT

+44 (0)20 3728 9500  
[info@ct.catapult.org.uk](mailto:info@ct.catapult.org.uk)  
[ct.catapult.org.uk](http://ct.catapult.org.uk)  
Twitter: @CGTCatapult

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154 4214 33.

We work with  
**Innovate UK**